Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial

Omuro, Antonio; A Brandes, Alba; F Carpentier, Antoine; Idbaih, Ahmed; A Reardon, David; Cloughesy, Timothy; Sumrall, Ashley; Baehring, Joachim; van den Bent, Martin; Bähr, Oliver; Lombardi, Giuseppe; Mulholland, Paul; Tabatabai, Ghazaleh; Lassen, Ulrik; Manuel Sepulveda, Juan; Khasraw, Mustafa; Vauleon, Elodie; Muragaki, Yoshihiro; Maria Di Giacomo, Anna; Butowski, Nicholas; Roth, Patrick; Qian, Xiaozhong; Z Fu, Alex; Liu, Yanfang; Potter, Von; Chalamandaris, Alexandros-Georgios; Tatsuoka, Kay; Lim, Michael; Weller, Michael

doi:10.1093/neuonc/noac099

Public

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Shared by NobleBlocks on Apr 14, 2022 • 12:00 AM UTC

Authors:

Antonio Omuro

Alba A Brandes

Antoine F Carpentier

Abstract

Abstract Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim of this open-label, phase III Che...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!